We describe a 4-generation fam ily in which a previously h ealth y 10-year-old boy died of late-onset orn ith in e transcarbam ylase (OTC) deficiency. P ed igree analysis and allopurinol loading tests in fem ale relatives w ere not inform ative. A m issense mutation (A208T) in the OTC g en e was detected in the deceased patient and in several clinically healthy male and fem ale relatives, the old est male being 97 years old. OTC deficiency was established in autopsy liver tissue of the propositus and liv er biopsy sam ples of his sister, mother, and a m aternal uncle* The m ales had 4% and 6% residual activity, re spectively, the fem ales 58% and 67%, respec tively. The observed relation betw een the m utation and the decreased OTC activity in liver tissue of th ese subjects suggests that the m utation is a d eleteriou s one. Late-on set, "m ild" OTC deficiency can have a fatal or a favorable outcom e. The disease can seg regate undetected in fam ilies. Am. 1997 Wiley-Liss, Inc,
INTRODUCTION
Ornithine transcarbam ylase (OTC) deficiency (McKusick #311250) is an X-linked recessive urea cycle disorder with variable clinical presentation in hemizygous males and heterozygous females [Tuchman, 1992] . The neonatal phenotype, often leading to early death, is caused by complete absence of hepatic OTC activity, It is accompanied by severe hyperammonemia, hypocitrullinemia, and orotic aciduria. Males with a partial (up to 30% of normal) enzyme deficiency generally are free of symptoms but may be at risk during catabolic circumstances and/or high protein intake [Finkelstein et al., 1990] . Onset in these patients has been reported at any age, the highest two being 46 and 58 years [Matsuda et al., 1991] , with symptoms characterized by pro tein avoidance, behavior changes, recurrent vomiting, lethargy, and coma [Drogari and Leonard, 1988] . Fe males heterozygous for OTC deficiency may be asym p tomatic or have similarly variable clinical symptoms which are explained by random X-chromosome inacti vation [Batshaw et al., 1986] , To date, approximately 70 m utations and polymor phisms in the OTC gene have been identified [Tuchman et al., 1995b] . Except for very few recurrent m utations such as the R141Q and R277W mutation, most patients with OTC deficiency have unique alterations. Thus far, there is no clear genotype-phenotype correlation [Oppliger et al., 1995] .
In this paper we present the results of clinical, bio chemical, and molecular genetic investigations per formed in a 4-generation family in which a previously healthy boy died of late-onset OTC deficiency at the age of 10 years. It is remarkable th a t his great-grandfather, who has transm itted the disease, remained asympto matic until the age of 97 years.
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The propositus (IV-5, Pig. 1), a 10-year-old boy, was adm itted because of a progressive hepato-encephalopathy in the course of a protracted viral gastroenteritis. Besides unexplained extreme irritability during minor illnesses with fever, noticed from the age of 6 years on, his medical history was uneventful. Physical exam ina tion on admission showed a severely ill child with peri odical restlessness, dry mucosa, a flushed face, wide pupils with a positive light reflex, alternating periods of bradycardia and tachycardia, slightly diminished deep tendon reflexes, and bilateral Babinski reflexes.
The initial blood ammonium level was 529 //mol/L {n < 60). Laboratory studies showed the following ab normal results: glutamine 2,404 /¿mol/L (n:596 ± 66), citrulline 14 //mol/L (n:35 ± 8), arginine 47 //mol/L (n:89 ± 20), ornithine 31 /¿mol/L (n:49 ± 14). Urine orotic acid was 760 mmol/mol creatinine (n: < 2 .5 ) and orotidine was 2.2 mmol/mol creatinine (n: < 2.5),
Following the recognition of hyperammonemia, pro tein intake was stopped immediately and a highcaloric carbohydrate infusion was started. Sodium benzoate (250 mg/kg body weight) was supplemented intravenously during the first two hours followed by 250 mg/kg bodyweight/24-h as a continuous infusion. This was supported by arginine-HCl, lactulose, folic acid and L-carnitine. Despite this treatm ent, th e pa tient's clinical condition worsened over the next hours, progressing to coma and convulsions. The blood ammonium level was still markedly elevated (530 //,mol/L). Anti-convulsive drug adm inistration, artifi cial ventilation and peritoneal dialysis were initiated. Unfortunately, hemodialysis, the most powerful tool for ammonia removal, could not be performed. ammonia levels norm alised only after 36 hours of treatm ent, however, w ithout any change in the p a tient's critical condition. Repeated EEG recordings showed an isoelectric p attern . All treatm en t was dis continued on th e 6th day after admission. One hour af ter death, autopsy was performed. C erebral edema, mild patchy bronchopneum onia and diffuse fatty changes of the liver were th e main abnorm alities.
The diagnosis of OTC deficiency was suspected. This was supported by low plasm a citrulline and increased urinary orotic acid. However, the pedigree (Fig. 1) was not informative for a fatal disorder w ith X~1 inked re-ceSvsive inheritance. In order to identify relatives at risk, biochemical investigations and DNA analyses were performed.
MATERIALS AND METHODS
Autopsy liver tissue of the propositus was stored at -70°C until use for enzyme studies, OTC activity was determined according to Kleijer et aL [1984] and ex pressed as a percentage of the control levels which ranged from 192 to 333 nmol/min/mg protein. The allopurinol loading test was performed as described by H auser et al, [1990] . The orotic acid and orotidine peak levels represent the m ean H -3 S.D., i.e., the maximum value th a t can be observed in controls [H auser et al., 1990] . Plasm a am m onium and amino acids were an a lyzed with an amino acid analyzer according to the m anufacturer's instructions. Orotic acid and orotidine were m easured by high performance liquid chromatog raphy using diode-array UV-detection. Genomic DNA was isolated from peripheral blood leukocytes, and m u tation analysis was performed by single-strand confor mational polymorphism (SSCP) and direct sequencing [Tsai et al., 1993] .
RESULTS
OTC activity in autopsy liver tissue of the propositus was 9 nmol/min/mg protein (4% of OTC activity in controls), confirming the suspected deficiency of this enzyme. SSCP analysis of the exons of the OTC gene showed a band shift of the polymerase chain reaction (PGR) product of exon 6 . Direct sequencing of the ab normal DNA fragm ent identified a A208T m utation in the propositus (data not shown). This m utation causes a substitution of alanine for threonine. Sequencing of all exons, including intron-exon junctions, showed no other* m utation. The A208T mutation was detected in the propositus* m other and sister, and in several other relatives (Fig. 1) . Four clinically healthy males (ages ranging from 2 to 97 years) were carriers of the mu tation.
The allopurinol loading test was performed in the fol lowing persons (Fig. 1 ): the mother (ILI-3), sister (IV-6), m aternal uncle (III-l) of the propositus as well as in II-1 , III-2, III-4, IV-3 and IV-9. All 3 m ales who were tested had abnorm al te st results, although the varia tion in the peak levels of orotic acid and orotidine was quite large (Table I ). In one female (III-2), urinary orotic acid and orotidine excretion were increased. In three of 4 abnormal allopurinol loading tests, the uri nary orotic acid was m arkedly higher th an orotidine, The results were norm al in th e other tested individuals (Table I) . Plasm a glutam ine, ano th er m arker of urea cycle disorders, was norm al in all asymptomatic rela tives (Table I ). In III-l, th e am m onia level increased from 44 /¿M to 204 pM (n:<60) after a protein-rich meal. D uring this episode of hyperam m onem ia, no neu rological or other symptoms were observed. There was a persistently low level of plasm a citrulline. Liver biopsy was performed in the m other (III-3), sister (IV-6) and m aternal uncle (III-l) of th e patient showing 170, 144 and 16 nmol/min/mg protein OTC activity, respec tively (Table I) . None of the heterozygous females (II-l, II-4, III-2, III-3, III-4 and IV-6, Fig. 1 ) ever had expe rienced clinical symptoms associated with OTC defi ciency.
DISCUSSION
OTC deficiency is anX -linked recessive disorder with a variable clinical phenotype. The dram atic clinical presentation in male infants is well-known. In patients with a partial enzyme deficiency, th e age of onset may vary. The clinical symptoms include bizarre behavior [DiMagno et al., 1986; Spada et al., 1994] and neuro logical abnorm alities [Drogari and Leonard, 1988] . M atsuda et al. 11991] have shown th a t late-onset OTC deficiency is a potentially lethal disorder. On the other hand, our family shows th a t symptom-free survival up to a very advanced age is also possible.
According to Pelet et al. [1990] the prior minimum risk of a m other of an affected male being a carrier is 84%. Recently, Tuchm an et al. [1995a] suggested that this risk is at least 90%. Thus, carrier detection is im portant when OTC deficiency is first diagnosed in a family. C arrier detection can be performed by in vivo testing (acute and chronic protein loading tests, allo purinol loading test), enzyme analysis in liver biopsy sam ples and molecular genetic investigations. With re spect to the allopurinol test, H auser et al. [1990] re ported th a t less then 5% of the obligate heterozygotes did have normal results. However, in the present fam ily, the allopurinol test was negative in 4-of the 5 fe males tested, indicating th at this test should not be used to identify female carriers in families with lateonset OTC deficiency.
In our family, 3 of 4 abnormal allopurinol loading tests showed a prevalence of urinary orotic acid over orotidine. This contrasts with the findings of Hauser et al. [1990] , who suggested th a t orotidine is a better m arker than orotic acid on allopurinol testing. The in dividual activities of pyrimidine nucleoside phosphorylase, catalyzing the conversion of orotidine to orotic acid, may influence the ratios of these two substances. Plasma glutamine is considered to be a m arker of urea cycle disorders, as it is formed from glutam ate and ex cess ammonia. In the present family, all tested asymp tomatic subjects had normal glutam ine levels. From th a t we conclude th at this analyte has no discrimina tive power in our family.
In families where the m utation is known, SSCP analysis of the OTC gene or direct sequencing are the methods of choice for carrier detection [Tsai et al., 1993] , We detected a A208T missense m uta Lion in the propositus. Sequencing of all exons, including intronexon junctions, showed no other m utation. The A208T mutation was present in several other relatives {Fig. 1 ). In 3 of them, liver OTC activity was measured (Table I) . The observed decreased OTC activity in two females and the low OTC activity in the propositus and his ma ternal uncle seems to confirm the deleterious nature of the mutation. The alanine at position 208 is evolution ary conserved among m am m alian OTC sequences and in more than 20 species [Tuchman et al., 1995b] , It is therefore highly suggestive th a t the alteration is not neutral. However, future expression studies of m utant cDNA are required to establish firmly the relationship between the mutation and the enzyme deficiency.
The OTC activity was not m easured in the great grandfather of the propositus. He was clinically L ate-O n set OTC D eficien cy 239 healthy at age 97 years. In the propositus and his uncle the OTC activity was 4% and 6%, respectively. The propositus died, while his uncle never has had major health problems. Apparently, factors other th an in vitro OTC activity play a role in the severity of symptoms, but this is not well understood [Finkelstein et al., 1990] .
To date, about 70 different m utations (including poly morphisms) have been identified in the OTC gene of patients with OTC deficiency [Tuchman et al., 1995b] . Most individuals with deficient enzyme activity have unique mutations, The A208T mutation was described previously in a large Polish pedigree with late-onset OTC deficiency IBakker et a l, 1995]. The m utation originated from the great-grandfather of the propositus who died at the age of 69 years without evidence of episodes of hyperammonemia.
In conclusion, we think th at OTC deficiency can seg regate undetected in families. When first diagnosed in a family, carrier detection is an im portant aspect of ge netic counselling. No relative can be reassured until molecular genetic and biochemical investigations have been performed. In the reported 4-generation family, late-onset OTC deficiency was caused by a missense (A208T) mutation. The disease can have a favorable as well as a fatal outcome. Consequently, it is im portant to identify individuals at risk.
